Drugs / MVA-EBNA1/LMP2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01800071 | Mar 2013 → Mar 2017 | Epstein-Barr virus infection, nasopharyngeal carcinoma | Cancer Research UK | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-EBNA1/LMP2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01800071 ↗ |
| Modality | Vaccine | “This clinical study is looking at a vaccine called MVA-EBNA1/LMP2.” NCT01800071 ↗ |